Axsome Therapeutics, Inc.: Axsome Therapeutics Announces FDA Approval of AUVELITY (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...

AMG Reports Financial and Operating Results for the First Quarter of 2026

Record AUM of $882 billion and record positive net client cash flows of more than $22 billion driven by ongoing momentum in alternative ...

Agnico Eagle Mines Limited: Agnico Eagle Reports First Quarter 2026 Results, Including Record Quarterly Operating Margins And Adjusted Net Income

"We delivered a solid start to 2026, achieving record operating margins while production and costs tracked well to plan. With gold production expected to be weighted to a stronger second half of the ...